Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients

General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre‐existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuznetsova, Anna, Lebedev, Aleksey, Gromov, Konstantin, Kazennova, Elena, Zazzi, Maurizio, Incardona, Francesca, Sönnerborg, Anders, Bobkova, Marina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813671/
https://www.ncbi.nlm.nih.gov/pubmed/35140966
http://dx.doi.org/10.1002/ccr3.5373
_version_ 1784644911530770432
author Kuznetsova, Anna
Lebedev, Aleksey
Gromov, Konstantin
Kazennova, Elena
Zazzi, Maurizio
Incardona, Francesca
Sönnerborg, Anders
Bobkova, Marina
author_facet Kuznetsova, Anna
Lebedev, Aleksey
Gromov, Konstantin
Kazennova, Elena
Zazzi, Maurizio
Incardona, Francesca
Sönnerborg, Anders
Bobkova, Marina
author_sort Kuznetsova, Anna
collection PubMed
description General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre‐existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full virological efficacy for first‐line RPV‐based ART regimens.
format Online
Article
Text
id pubmed-8813671
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88136712022-02-08 Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients Kuznetsova, Anna Lebedev, Aleksey Gromov, Konstantin Kazennova, Elena Zazzi, Maurizio Incardona, Francesca Sönnerborg, Anders Bobkova, Marina Clin Case Rep Case Reports General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre‐existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full virological efficacy for first‐line RPV‐based ART regimens. John Wiley and Sons Inc. 2022-02-03 /pmc/articles/PMC8813671/ /pubmed/35140966 http://dx.doi.org/10.1002/ccr3.5373 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Kuznetsova, Anna
Lebedev, Aleksey
Gromov, Konstantin
Kazennova, Elena
Zazzi, Maurizio
Incardona, Francesca
Sönnerborg, Anders
Bobkova, Marina
Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
title Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
title_full Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
title_fullStr Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
title_full_unstemmed Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
title_short Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
title_sort pre‐existing singleton e138a mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813671/
https://www.ncbi.nlm.nih.gov/pubmed/35140966
http://dx.doi.org/10.1002/ccr3.5373
work_keys_str_mv AT kuznetsovaanna preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients
AT lebedevaleksey preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients
AT gromovkonstantin preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients
AT kazennovaelena preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients
AT zazzimaurizio preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients
AT incardonafrancesca preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients
AT sonnerborganders preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients
AT bobkovamarina preexistingsingletone138amutationsinthereversetranscriptasegenedonotaffecttheefficacyoffirstlineantiretroviraltherapyregimensusingrilpivirineinhumanimmunodeficiencyvirusinfectedpatients

Ejemplares similares